摘要
目的探讨对慢性阻塞性肺疾病急性加重患者实施降钙素原检测的临床价值。方法选择该院2017年10月—2019年2月收治的120例慢性阻塞性肺疾病患者作为实验对象;依据慢阻肺有无呈现出急性加重展开分组;比照组(60例):未表现出急性加重的现象;实验组(60例):表现出急性加重的现象;临床对两组慢性阻塞性肺疾病患者静脉血液样本进行抽取,合理展开PCT(降钙素原)水平以及CRP(C-反应蛋白)测定工作,并且就实验组患者基本情况展开对应性治疗,最终就两组慢阻肺患者测定结果以及实验组治疗结果展开对比。结果实验组PCT水平为(3.25±0.85)μg/L,CRP水平为(22.49±3.03)mg/L;比照组PCT水平为(1.19±0.43)μg/L,CRP水平为(4.85±0.62)mg/L;最终发现,实验组慢性阻塞性肺疾病急性加重患者PCT水平以及CRP水平均高于比照组明显,差异有统计学意义(t=16.751 1,44.179 9,P<0.05);治疗前,实验组PCT水平为(3.25±0.85)μg/L,CRP水平为(22.49±3.03)mg/L;治疗后,PCT水平为(1.42±0.42)μg/L,CRP水平为(8.25±1.02)mg/L;最终发现,实验组慢性阻塞性肺疾病急性加重患者治疗后PCT水平以及CRP水平均低于治疗前,差异有统计学意义(t=14.951 0,34.501 0,P<0.05)。结论慢性阻塞性肺疾病急性加重患者于临床接受检验期间,PCT水平以及CRP水平的顺利检测,对于疗效评价以及预后判断可以获得显著效果,最终可对慢性阻塞性肺疾病急性加重患者预后水平的提升,奠定基础。
Objective To investigate the clinical value of procalcitonin in patients with acute exacerbation of chronic obstructive pulmonary disease. Methods 120 patients with chronic obstructive pulmonary disease admitted to our hospital from October 2017 to February 2019 were selected as subjects. According to the presence or absence of acute obstructive pulmonary disease, the group was presented with acute exacerbation. The comparison group (60 cases): not shown acute exacerbation;experimental group (60 cases): showed acute exacerbation;clinically, venous blood samples were taken from two groups of patients with chronic obstructive pulmonary disease, and PCT (procalcitourin) levels and CRP (C-Reactive protein) were reasonably developed, measurement work, and the corresponding treatment of the basic conditions of the experimental group patients, and finally the results of the two groups of chronic obstructive pulmonary disease patients and the experimental group treatment results. Results The PCT level of the experimental group was (3.25±0.85)μg/L, and the CRP level was (22.49±3.03) mg/L;the PCT level of the comparison group was (1.19±0.43)μg/L, and the CRP level was (4.85±0.62) mg/L;finally found that the PCT level and CRP level in patients with acute exacerbation of chronic obstructive pulmonary disease in the experimental group were significantly higher than those in the control group,the difference was statistically significant(t=16.751 1, 44.179 9,P<0.05);before treatment, the PCT level in the experimental group was (3.25±0.85)μg/L, CRP level was (22.49±3.03)mg/L;after treatment, PCT level was (1.42±0.42)μg/L, CRP level was (8.25±1.02) mg/L;finally found that the experiment The PCT level and CRP level in patients with acute exacerbation of chronic obstructive pulmonary disease were significantly lower than those before treatment,the difference was statistically significant(t=14.951 0, 34.501 0,P<0.05). Conclusion During the clinical examination of patients with acute exacerbation of chronic obstructive pulmonary disease, the smooth detection of PCT level and CRP level can achieve significant effects on the evaluation of efficacy and prognosis, and ultimately lay the foundation for the prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease.
作者
杨艾华
YANG Ai-hua(Department of Clinical Laboratory,Lincang People's Hospital,Lincang,Yunnan Province,677000 China)
出处
《世界复合医学》
2019年第8期105-107,共3页
World Journal of Complex Medicine
关键词
慢性阻塞性肺疾病
急性加重
降钙素原
临床检测
Chronic obstructive pulmonary disease
Acute exacerbation
Procalcitonin
Clinical detection
